1622 related articles for article (PubMed ID: 1727833)
1. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
2. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
3. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
4. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
[TBL] [Abstract][Full Text] [Related]
5. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone.
Behre HM; Kliesch S; Lemcke B; von Eckardstein S; Nieschlag E
Hum Reprod; 2001 Dec; 16(12):2570-7. PubMed ID: 11726576
[TBL] [Abstract][Full Text] [Related]
6. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
7. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
8. Endocrine approaches to male fertility control.
Knuth UA; Nieschlag E
Baillieres Clin Endocrinol Metab; 1987 Feb; 1(1):113-31. PubMed ID: 3297020
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
Matsumoto AM
J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
[TBL] [Abstract][Full Text] [Related]
10. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
[TBL] [Abstract][Full Text] [Related]
11. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
[TBL] [Abstract][Full Text] [Related]
12. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
[TBL] [Abstract][Full Text] [Related]
13. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen.
Bhasin S; Yuan QX; Steiner BS; Swerdloff RS
J Clin Endocrinol Metab; 1987 Sep; 65(3):568-74. PubMed ID: 3114307
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
Guerin JF; Rollet J
Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial of 19-nortestosterone-hexoxyphenylpropionate (Anadur) for male fertility regulation.
Knuth UA; Behre H; Belkien L; Bents H; Nieschlag E
Fertil Steril; 1985 Dec; 44(6):814-21. PubMed ID: 3935486
[TBL] [Abstract][Full Text] [Related]
16. Developments in the control of testicular function.
Swerdloff RS; Wang C; Bhasin S
Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
[TBL] [Abstract][Full Text] [Related]
18. Suppression of human spermatogenesis by testosterone implants.
Handelsman DJ; Conway AJ; Boylan LM
J Clin Endocrinol Metab; 1992 Nov; 75(5):1326-32. PubMed ID: 1430094
[TBL] [Abstract][Full Text] [Related]
19. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
Meriggiola MC; Bremner WJ; Paulsen CA; Valdiserri A; Incorvaia L; Motta R; Pavani A; Capelli M; Flamigni C
J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868
[TBL] [Abstract][Full Text] [Related]
20. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
